Patrick Chène

ATPases as drug targets: learning from their structure

P. Chène, Patrick Chène, 2002, Nature Reviews Drug Discovery.

Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue

Joseph Schoepfer, Pascal Furet, R. Schmitz, 2009, BMC Chemical Biology.

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.

Joerg Kallen, Pascal Furet, Keiichi Masuya, 2015, Journal of medicinal chemistry.

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Joseph Schoepfer, Michael Rugaard Jensen, Robert Cozens, 2008, Breast Cancer Research.

Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.

P. Chène, Patrick Chène, 2004, Molecular cancer research : MCR.

The role of tetramerization in p53 function

P. Chène, Patrick Chène, 2001, Oncogene.

Drugs Targeting Protein–Protein Interactions

P. Chène, Patrick Chène, 2006, ChemMedChem.